In this retrospective study, the genetic and COO characteristics of CD5+ and CD5- DLBCL were investigated by GEP and the LymphGen algorithm, with the aim to identify the molecular factors associated with prognosis and to develop personalized treatment. The gene discussed is CD5; the disease is diffuse large B-cell lymphoma.